Journal of Diabetes Investigation: Volume 14, Issue 1 Summary
The January 2023 issue of the Journal of Diabetes Investigation brings together key scientific advancements spanning fundamental laboratory discoveries to practical clinical insights. Major research themes in this issue focus on the future of diabetes therapies, identifying novel molecular pathways, and managing long-term complications of the disease.
Notable highlights include a review of stem cell prospects for healing diabetic blood vessel and nerve complications, a historical look at the evolution of insulin therapy toward cellular replacement, and a clinical study demonstrating how a brief two-week comprehensive risk management program can rapidly improve lipid (fatty acid) profiles in patients with type 2 diabetes. Additionally, researchers explore the biological mechanisms of how metformin works at a cellular level and how specific proteins control glucose transport inside fat cells.
For patients and families, these findings emphasize that diabetes care is continuously evolving. From highly structured, short-term lifestyle and clinical interventions that yield immediate health benefits to long-term research in stem cells and beta-cell transplantation, the future of diabetes management points toward more personalized, effective, and biology-driven treatments.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
Prospects of stem cell therapy for diabetic microvascular complications
Author: Keiko Naruse
Research Objective: To evaluate the potential and mechanisms of clinical applications of stem cell transplantation for treating microvascular (small blood vessel) complications caused by diabetes.
Methods: This review synthesizes existing scientific understanding regarding stem cell transplantation and its physiological impacts on tissues affected by chronic diabetes complications.
Main Findings: Stem cell transplantation has been shown to improve biological abnormalities in tissues. It achieves these improvements primarily through three pathways: promoting the growth and protection of new blood vessels (angiogenesis/protection), supporting the growth and protection of damaged nerves, and delivering powerful anti-inflammatory effects.
Clinical Significance & Patient Key Points: High blood sugar can damage small blood vessels and nerves over time, leading to complications in the eyes, kidneys, and extremities. While still an emerging field, stem cell therapy holds significant promise because it does not just manage symptoms; it aims to physically repair and protect damaged blood vessels and nerves from within.
Association between diabetes mellitus and post‐stroke cognitive impairment
Authors: Kang‐Po Lee, Jung‐Sheng Chen, Chih‐Yuan Wang
Research Objective: To examine how diabetes mellitus relates to post-stroke cognitive impairment (PSCI) and post-stroke dementia (PSD), and to identify predictive tools and preventative strategies.
Methods: The authors reviewed the structural and pathological changes in the brains of stroke survivors with diabetes. They evaluated the clinical roles of high blood sugar (hyperglycemia), low blood sugar (hypoglycemia), and traditional biomarkers like HbA1c, alongside modern predictive markers.
Main Findings: Diabetes worsens brain pathology after a stroke, affecting post-stroke inflammation, nerve remodeling, and brain repair. High glycemic variability (frequent blood sugar swings), glycemic extremes (both high and low blood sugar), and compounds like the receptor for advanced glycation end products (RAGE) and gut microbiota are emerging as valuable predictors of cognitive decline after a stroke, alongside standard HbA1c tests.
Clinical Significance & Patient Key Points: Stroke survivors with diabetes face a higher risk of cognitive decline. Stabilizing blood sugar levels—specifically avoiding both spikes and sudden drops—is vital to protecting brain function and preventing post-stroke dementia. Discussing blood sugar variability and gut health with your medical team may provide better insight into long-term cognitive health.
Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
Authors: Marie Okubo, Yuji Hataya, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka
Research Objective: To document a rare case of a patient recovering from insulin dependence after developing diabetes caused by a cancer immunotherapy drug.
Methods: The authors detailed the clinical progression of a 54-year-old male with lung cancer treated with pembrolizumab (an immune checkpoint inhibitor). He developed secondary adrenal insufficiency, followed by severe high blood sugar with ketosis. A glucagon challenge test confirmed insulin-dependent diabetes. Pembrolizumab was discontinued due to drug-induced liver inflammation (hepatitis).
Main Findings: Six months after discontinuing the immunotherapy drug, a repeat glucagon challenge showed that the patient’s natural insulin secretion had recovered, allowing him to safely stop insulin therapy. Concurrently, his lung cancer lesions continued to shrink.
Clinical Significance & Patient Key Points: Diabetes caused by cancer immunotherapies (ICI-DM) is typically considered permanent. This unique case demonstrates that if the offending immunotherapy drug is stopped early due to complications, a patient's pancreas may recover its ability to make insulin. This suggests that lifelong insulin therapy might not always be inevitable for patients experiencing this rare drug side effect.
New mechanism of metformin action mediated by lysosomal presenilin enhancer 2
Authors: Kenji Sugawara, Wataru Ogawa
Research Objective: To uncover the molecular-level pathways through which metformin, the most widely prescribed type 2 diabetes medication, acts within body cells.
Methods: This laboratory study examined the direct interactions between metformin and a specific cell protein complex called PEN2 (presenilin enhancer 2) inside cell lysosomes (the cells' recycling centers).
Main Findings: Metformin binds directly to the protein PEN2, forming a complex with another protein (ATP6AP1). This reaction blocks a specific cell enzyme activity (v-ATPase) and brings other key proteins (AXIN/LKB1) to the lysosomes. Ultimately, this chain reaction activates AMPK, a crucial cellular sensor that helps lower blood sugar and improve metabolic health.
Clinical Significance & Patient Key Points: Although metformin has been used successfully for decades, scientists are still mapping exactly how it works on a molecular level. This study identifies a specific protein receptor (PEN2) as a primary target for metformin, which helps explain its powerful, blood-sugar-lowering benefits and could pave the way for designing more targeted metabolic drugs in the future.
SNAP29 regulates the intracellular sequestration of glucose transporter 4 (GLUT4) vesicles in adipocytes
Authors: Kumiko Matsui, Masahiro Emoto, Naofumi Fukuda, Ryuta Nomiyama, Kyoko Yamada, Yukio Tanizawa
Research Objective: To investigate how the protein SNAP29 controls the storage and movement of glucose transporter 4 (GLUT4)—the vehicle that carries glucose into fat cells—in response to insulin.
Methods: Using cell cultures (3T3-L1 adipocytes), researchers utilized mass spectrometry, western blotting, microscopy, and gene-silencing techniques to observe where SNAP29 is located and how it interacts with other proteins during glucose uptake.
Main Findings: Under resting conditions, SNAP29 acts like an anchor in the cell's center, holding GLUT4-containing packages (vesicles) in place by binding to another protein (syntaxin6). When SNAP29 was either over-expressed or completely silenced, glucose uptake in response to insulin was disrupted. Over-expressing it kept GLUT4 locked up, while silencing it caused the GLUT4 packages to scatter aimlessly through the cell.
Clinical Significance & Patient Key Points: In healthy individuals, insulin signals fat and muscle cells to bring glucose transporters (GLUT4) to the cell surface to absorb sugar from the blood. This study identifies SNAP29 as a critical "anchor" that keeps these transporters organized and ready for action. Disruptions to this anchoring system may contribute to insulin resistance, a core feature of type 2 diabetes.
Change in fatty acid composition of plasma triglyceride caused by a 2 week comprehensive risk management for diabetes
Authors: Naohiro Taya, Naoto Katakami, Kazuo Omori, Shigero Hosoe, Hirotaka Watanabe, Mitsuyoshi Takahara, et al.
Research Objective: To track short-term changes in specific types of triglycerides (blood fats) and their fatty acid structures following an intensive, two-week hospital-based diabetes management program.
Methods: A prospective observational study of 31 hospitalized type 2 diabetes patients undergoing intensive glycemic and lifestyle therapy. Blood plasma lipid profiles were measured on day 2 and day 16 using highly sensitive mass spectrometry to analyze 104 different triglyceride types.
Main Findings: Most triglyceride levels decreased after the two-week management program. In particular, triglycerides with simpler structures (fewer carbon atoms and fewer double bonds) showed the largest drops. Most notably, triglycerides containing a fatty acid called myristic acid (FA 14:0) saw the most dramatic and statistically significant reduction (over 50% decrease).
Clinical Significance & Patient Key Points: High triglycerides are common in diabetes and increase heart disease risk. This study highlights that a comprehensive, short-term health program (incorporating diet, exercise, and medical management) doesn't just lower overall fat levels; it preferentially reduces the specific, simple saturated fatty acids (like myristic acid) that are strongly linked to cardiovascular risks.
Advances in insulin therapy from discovery to β‐cell replacement
Authors: Teruaki Sakurai, Sodai Kubota, Takehiro Kato, Daisuke Yabe
Research Objective: To trace the historical milestones of insulin development and outline the future landscape of biological treatments for diabetes.
Methods: A comprehensive review outlining the journey of insulin therapies over the last century, detailing the transition from animal-derived insulin to recombinant human insulin, and projecting future cellular therapies.
Main Findings: Since the 1920s revolution of extracting insulin from animal pancreases, gene cloning technology has enabled highly effective, bio-engineered human insulin formulations. The review highlights that the next massive paradigm shift in the coming decades is expected to be beta-cell (β-cell) replacement therapy, where new, functioning, insulin-producing cells are transplanted directly into patients.
Clinical Significance & Patient Key Points: For a century, insulin has been a life-saving daily requirement for millions of individuals. Scientific research is steadily moving away from simply injecting insulin toward cellular cures—such as replacing damaged insulin-producing beta-cells—which could eventually eliminate the need for daily injections for many patients.
